Tauns Laboratories (TSE:197A) Operating Income : 円 Mil (TTM As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Tauns Laboratories Operating Income?

Tauns Laboratories's Operating Income for the six months ended in Jun. 2024 was 円8,030 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Tauns Laboratories's Operating Income for the six months ended in Jun. 2024 was 円8,030 Mil. Tauns Laboratories's Revenue for the six months ended in Jun. 2024 was 円18,435 Mil. Therefore, Tauns Laboratories's Operating Margin % for the quarter that ended in Jun. 2024 was 43.56%.

Tauns Laboratories's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Tauns Laboratories's annualized ROC % for the quarter that ended in Jun. 2024 was 34.85%. Tauns Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 76.81%.

Tauns Laboratories Operating Income Historical Data

The historical data trend for Tauns Laboratories's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tauns Laboratories Operating Income Chart

Tauns Laboratories Annual Data

Trend

Jun22

Jun23

Jun24

Operating Income

11,189.56

4,967.28

8,030.10

Tauns Laboratories Semi-Annual Data
	Jun22	Jun23	Jun24
Operating Income	11,189.56	4,967.28	8,030.10

Tauns Laboratories Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 was 円 Mil.

Tauns Laboratories (TSE:197A) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Tauns Laboratories's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	8030.098 * ( 1 - 26.3% )	/	( (15451.687	+	18513.102)	/ 2 )
=	5918.182226	/	16982.3945
=	34.85 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	18332.162	-	1636.1	-	( 1244.375	-	max(0, 6517.961	-	9456.91	+	1244.375	))
=	15451.687

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	29261.325	-	4306.951	-	( 9424.891	-	max(0, 10474.442	-	16915.714	+	9424.891	))
=	18513.102

Note: The Operating Income data used here is one times the annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Tauns Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	7865.902	/	( ( (4402.141 + max(5926.574, 0))	+	(7905.227 + max(2248.381, 0)) )	/	2 )
=	7865.902	/	( ( 10328.715	+	10153.608 )	/	2 )
=	7865.902	/	10241.1615
=	76.81 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3051.248	+	4586.923	+	574.364)	-	(1636.1	+	0	+	649.861)
=	5926.574

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2706.864	+	4717.448	+	66.510999999999)	-	(4306.951	+	0	+	935.491)
=	2248.381

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Jun. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Tauns Laboratories's Operating Margin % for the quarter that ended in Jun. 2024 is calculated as:

Operating Margin %	=	Operating Income (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	8030.098	/	18434.863
	=	43.56 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Tauns Laboratories Operating Income Related Terms

Thank you for viewing the detailed overview of Tauns Laboratories's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Tauns Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tauns Laboratories Inc (TSE:197A) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

761-1 Kamishima Izunokuni-shi, Shizuoka, JPN, 410-2325

Website

https://www.tauns.co.jp/en

Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.

Tauns Laboratories Headlines

No Headlines